ModernaMRNAEarnings & Financial Report
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
MRNA Q3 2025 Key Financial Metrics
营收
$1.0B
毛利润
$809.0M
营业利润
$-260.0M
净利润
$-200.0M
毛利率
79.6%
营业利润率
-25.6%
净利率
-19.7%
同比增长
-45.4%
EPS
$-0.51
资金流向
Moderna Q3 2025 Financial Summary
Moderna reported revenue of $1.0B for Q3 2025, with a net profit of $-200.0M (-19.7% margin). Cost of goods sold was $207.0M, operating expenses totaled $1.1B.
Key Financial Metrics
| Total Revenue | $1.0B |
|---|---|
| Net Profit | $-200.0M |
| Gross Margin | 79.6% |
| Operating Margin | -25.6% |
| Report Period | Q3 2025 |
Moderna Annual Revenue by Year
Moderna annual revenue history includes year-by-year totals (for example, 2024 revenue was $3.2B).
| Year | Annual Revenue |
|---|---|
| 2024 | $3.2B |
| 2023 | $6.8B |
| 2022 | $19.3B |
利润表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $2.81B | $167.0M | $241.0M | $1.86B | $966.0M | $108.0M | $142.0M | $1.02B |
| 同比增长 | -44.7% | -91.0% | -29.9% | 1.7% | -65.6% | -35.3% | -41.1% | -45.4% |
资产负债表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $18.43B | $16.73B | $15.68B | $15.80B | $14.14B | $12.70B | $12.01B | $12.13B |
| 总负债 | $4.57B | $3.91B | $3.97B | $3.88B | $3.24B | $2.64B | $2.61B | $2.81B |
| 股东权益 | $13.85B | $12.82B | $11.71B | $11.93B | $10.90B | $10.07B | $9.40B | $9.33B |
现金流量表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $622.0M | $-989.0M | $-1.27B | $-1.57B | $825.0M | $-1.04B | $-919.0M | $-847.0M |
Other Health Care Companies
ABBV
AbbVie
营收
$15.8B
净利润
$186.0M
AMGN
Amgen
营收
$9.9B
净利润
$1.3B
BIIB
Biogen
营收
$2.3B
净利润
$-48.9M
GILD
Gilead Sciences
营收
$7.8B
净利润
$3.1B
INCY
Incyte
营收
$1.5B
净利润
$299.3M
REGN
Regeneron Pharmaceuticals
营收
$3.9B
净利润
$844.6M
VRTX
Vertex Pharmaceuticals
营收
$3.2B
净利润
$1.2B
ABT
Abbott Laboratories
营收
$11.4B
净利润
$1.6B
A
Agilent Technologies
营收
$1.9B
净利润
$434.0M
ALGN
Align Technology
营收
$995.7M
净利润
$56.8M